Continue the legacy of protection

Stock the one and only RhoGAM

How to Order

A history of innovations

Throughout its over 50-year history, RhoGAM has incorporated innovations to remain the #1 selling anti-D brand.1 Year after year, RhoGAM remains a reliable choice.

Only RhoGAM has been consistently available across 5 decades with no interruptions in supply2

1968: Approval of RhoGAM

1979: Approval of MICRhoGAM

1985: Prefilled, ready-to-use syringe available

1991: New Indications. Percutaneous umbilical cord sampling (PUBS) Chorionic villus sampling (CVS)

2001: Safety Shield. Designed to offer protection from needle sticks by completely encompassing the needle once engaged.

2007: RhoGAM Ultra-Filtered PLUS approved

2018 RhoGAM 50-year anniversary

Continue the RhoGAM legacy of protection

You can order RhoGAM through Kedrion Biopharma Customer Service or your Authorized Distributor

RhoGAM Ordering Infromation

NDC # Description Unit Measure Quantity Level
0562-7805-01 RhoGAM Ultra-Filtered PLUS EA 1 pack
0562-7805-05 RhoGAM Ultra-Filtered PLUS EA 5 packs
0562-7805-25 RhoGAM Ultra-Filtered PLUS EA 25 packs

Customer Service Contact Information

Phone: (855) 353-7466

Fax: (855) 751-7951


Hours: Mon-Fri 8:00am - 6pm CT

The RhoGAM story never gets old

RhoGAM is the #1 selling anti-D breakthrough that continues to make life-saving history1

The remarkable true story of one of the greatest medical breakthroughs of the 20th century.

Before the 1960s, there was no method available to prevent Rh immunization during Rh-incompatible pregnancies, which could result in hemolytic disease of the fetus and newborn (HDFN). At that time, HDFN affected 9%-10% of all pregnancies and contributed significantly to fetal deaths in the US.3 Innovators were needed for this complex problem.

"Before it's a breakthrough it's a crazy idea."

A team of scientists were convinced that the answer could be what was then an unconventional theory. Known as passive antibody immunosuppression, an active immune response is prevented by passive administration of antibodies directed to the stimulus4-6 Based on this idea, it was theorized that administering passively administered anti-D immunoglobulin to Rh-negative mothers could help prevent Rh sensitization.

"A story of heroism and triumph. Of brilliant science and generous empathy."

Before the 1960s, employing passive antibody immunosuppression to garner an immune response was not well received. But the research team remained dedicated to this idea to reduce Rh-sensitivity. As a result, in 1968, the FDA approved the use of RhoGAM to help prevent Rh sensitization.7 As the first anti-D product available, RhoGAM has given hope to Rh-negative mothers by protecting generations of Rh-positive babies for five decades.2,8-10